Amarin shares trading at $0.59- 0.60, values we have not seen for quite some time. Potential tariffs on generic products made/manufactured abroad may be a factor. Customs holding such products at port entry, preventing distribution and sale elsewhere in the country may be another. CNN reported a few hours ago that the Attorney General nominee from Florida has opposed generic products that cause elevated drug prices in the United States. I have a bottle of one such generic product that cost me far more than the $9-$15 co-pay I used to pay for a 3-month refill of Brand Vascepa prior to 7/01/2024. Remember the recent CAFC observation that the Hikma product has not been FDA-approved for CVD indications, nor was there record evidence that such product was a therapeutic
equivalent of Amarin's brand Vascepa.
Market Data 
Markets 
AI
